Research Analysts Set Expectations for AUTL FY2025 Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Investment analysts at William Blair decreased their FY2025 earnings estimates for shares of Autolus Therapeutics in a research note issued to investors on Wednesday, November 12th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($0.95) for the year, down from their previous forecast of ($0.79). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. William Blair also issued estimates for Autolus Therapeutics’ Q4 2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at ($0.46) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The firm had revenue of $21.14 million during the quarter, compared to analysts’ expectations of $21.08 million.

AUTL has been the subject of several other research reports. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, November 3rd. Wells Fargo & Company reduced their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.15.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.37 on Monday. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $3.45. The stock’s fifty day moving average price is $1.50 and its two-hundred day moving average price is $1.81. The firm has a market cap of $364.61 million, a PE ratio of -1.65 and a beta of 1.84.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marex Group plc bought a new position in Autolus Therapeutics in the 2nd quarter valued at $28,000. R Squared Ltd purchased a new stake in shares of Autolus Therapeutics in the second quarter worth $50,000. Invesco Ltd. boosted its stake in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the period. Delaney Dennis R bought a new stake in Autolus Therapeutics during the second quarter valued at $55,000. Finally, Forefront Wealth Management Inc. purchased a new position in Autolus Therapeutics during the second quarter worth about $61,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.